Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
InSightec
Age
50–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Biopsy proven adenocarcinoma of the prostate
Intermediate risk, organ-confined prostate cancer (T1a up to T2b) and voluntarily chooses Exablate, who may currently be on watchful waiting or active surveillance and not in need of imminent radical therapy
Up to 2 MRI visible Gleason 7 confirmed on mapping prostate biopsy that Investigator deems treatable within a single treatment session; may have secondary Gleason 6 on ipsilateral or contralateral side confirmed with biopsy and/or MRI
PSA less than or equal to 20ng/mL
You may not be if
Evidence of distant prostate cancer including lymph node involvement and/or metastasis of cancer
Subject undergoing androgen deprivation therapy, initiating any new medication that can affect PSA, or history of bilateral orchiectomy
Active bladder cancer, active UTI, or untreated prostatitis
Prostate-specific chemotherapy, brachytherapy, cryotherapy, photodynamic therapy, radical prostatectomy, or focal therapy (excluding FUS); or any prior radiation therapy to the pelvis for prostate cancer or any other malignancy
Subjects with pathology or implants that may adversely impact treatment due to acoustics, imaging, or safe probe insertion
Subject not able or willing to tolerate the required prolonged stationary supine position during treatment
Contraindications to MRI
Clareo Health | Continued Access of Focal MR-Guided Focused Ultrasound for Localized Intermediate Risk Prostate Lesions
